Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Normothermia in Patients With Acute Cerebral Damage

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2007 by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico.
Recruitment status was:  Recruiting
Information provided by:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Identifier:
First received: June 25, 2007
Last updated: September 19, 2007
Last verified: June 2007
The purpose of our study is to verify wherever normothermia (achieved with diclofenac administration) may improve intracranial pressure control and may limit secondary cerebral damage thus positively influencing outcome in patients with acute cerebral damage admitted to ICU.

Condition Intervention Phase
Traumatic Brain Injury
Subarachnoid Hemorrhage
Drug: Diclofenac
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Normothermia in Patients With Acute Cerebral Damage

Resource links provided by NLM:

Further study details as provided by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico:

Primary Outcome Measures:
  • Maintenance of normothermia [ Time Frame: within 14 days from ICU admission ]

Secondary Outcome Measures:
  • Behaviour of intracranial pressure and cerebral perfusion pressure. Influence on six month outcome. [ Time Frame: Within 14 days from ICU admission/Six months ]

Study Start Date: June 2007
Estimated Study Completion Date: June 2009
Detailed Description:

Pyrexia can exacerbate ischemic neuronal damage and physiological dysfunction after traumatic brain injury and subarachnoid hemorrhage.Fever also represent an important issue occurring in 78% of patients with acute cerebral damage admitted to intensive care unit (ICU). For those patients, normothermia is actually recommended in order to reduce secondary cerebral damage and to control intracranial pressure, that are known to worsen long term prognosis. Our primary endpoint is to maintain normothermia in patients with acute cerebral damage (axillary temperature < 38°C or internal temperature < 38,8°C) administering diclofenac. We will also investigate the corresponding behaviour of intracranial pressure and cerebral perfusion pressure.

Comparison(s): We will compare two different doses of subcutaneous diclofenac (0,35 mg/kg - 1/3 a vial - vs 0,5 mg/Kg - 1/2 vial) to continuous intravenous of 0,48 mg/kg diclofenac for 12 hours.


Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with severe traumatic injury or subarachnoid hemorrhage in coma (GCS<8), intubated, mechanically ventilated with intracranial pressure (ICP) and invasive arterial pressure monitoring

Exclusion Criteria:

  • Know adverse reactions with NSAI
  • Platelets count < 20,000/dl
  • Gastric or duodenal ulceration in active phase
  • Hepatic insufficiency, cirrhosis or previous liver transplant
  • Acute or chronic renal insufficiency
  • Coronary insufficiency, acute myocardial infarct in the previous 6 month
  • Barbiturate coma
  • Patients in therapy with acetylsalicylic acid, lithium, digoxin, methotrexate and cyclosporin.
  • Known or suspected pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00491192

Contact: Nino Stocchetti, MD 0039.02.5503.5517

Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena Recruiting
Milan, Italy, 20122
Sub-Investigator: Laura Ghisoni, MD         
Principal Investigator: Katia Canavesi, MD         
Sponsors and Collaborators
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Study Director: Nino Stocchetti, MD Ospedale Maggiore Policlinico Mangiagalli e Regina Elena
  More Information Identifier: NCT00491192     History of Changes
Other Study ID Numbers: 1575
Study First Received: June 25, 2007
Last Updated: September 19, 2007

Keywords provided by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico:
Acute cerebral damage
Intracranial pressure
Cerebral perfusion pressure
Traumatic brain injury
Subarachnoid hemorrhage

Additional relevant MeSH terms:
Brain Injuries
Subarachnoid Hemorrhage
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System
Wounds and Injuries
Pathologic Processes
Intracranial Hemorrhages
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017